Clinical Trials Directory

Trials / Completed

CompletedNCT02113800

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
AIO-Studien-gGmbH · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is designed as an open-label, prospective, single arm, multicenter study of everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3 after failure of first-line platin-based chemotherapy (open-label pilot study). The aim of this study is to provide a second line therapy to patients with any type of platinum based first line chemotherapy, to gather data on disease control rate and progression free survival.

Detailed description

As more efficient drugs are urgently needed for the treatment of neuroendocrine tumors the investigator evaluated phosphorylated Mammalian target of rapamycin (mTOR) and effectors in a series of NEC G3 at the Charité Center. Everolimus showed antiproliferative effects in bronchial NET. In a second approach the data of this study should be the basis to generate another study to further explore everolimus as maintenance therapy in NEC G3/ NET G3.

Conditions

Interventions

TypeNameDescription
DRUGEverolimus (Afinitor®)Formulation: 10 mg/day Route: oral (tablet)

Timeline

Start date
2015-08-01
Primary completion
2020-04-01
Completion
2020-04-01
First posted
2014-04-15
Last updated
2020-10-28

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02113800. Inclusion in this directory is not an endorsement.